Clinical trial
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic…
NCT00093366 · Fred Hutchinson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00093366 |
|---|---|
| Title | Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes |
| Official title | Therapy of Advanced Stage Myelodysplastic Syndrome (MDS) With Arsenic Trioxide Given in Combination With Etanercept: A Phase I/II Study |
| Lead sponsor | Fred Hutchinson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases |
| Intervention type | Biological, Drug |
| Interventions | etanercept, arsenic trioxide |
| Enrollment | 32 |
| Start date | Jun 1, 2004 |
| Completion | Jul 1, 2006 |
| First posted | Oct 8, 2004 |
| Last update posted | Nov 30, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: